单位：[1]China–Japan Friendship Hospital, Beijing, China[2]The First Affiliated Hospital, Peking University, Beijing, China[3]The First Affiliated Hospital, China Medical University, Shenyang, China[4]The Union Hospital, Huazhong Technology University, Wuhan, China华中科技大学同济医学院附属协和医院[5]The Second Affiliated Hospital of Sun Yat-sen University, Guangzhou, China中山大学附属第二医院[6]The Changhai Hospital, Second Military Medical University, Shanghai, China[7]Tianjin Medical University General Hospital, Tianjin, China[8]Henan Provincial People’s Hospital, Henan, China
Aims: To explore safety and efficacy of BIAsp 30 as initiation or replacement therapy in routine clinical practice in patients with poorly controlled diabetes in the Chinese cohort of the IMPROVE study. Methods: In the 26-week, non-interventional, observational study, Chinese subjects with diabetes started BIAsp 30 treatment in routine care. Data from patients' diaries and medical records were transferred to CRFs by participating physicians. Clinical trial registration: NCT00659282. Results: Of the 21,729 subjects enrolled (mean age 54.0 years, BMI 24.6 kg/m(2), diabetes duration 4.86 years), 32.3% were treatment-naive, 59.3% were from oral anti-diabetic drugs (OADs) only and 8.1% were from insulin +/- OADs. Overall, mean HbA(1c) and FBG decreased by 2.82% and 5 mmol/L, respectively. In the subgroups, changes were: -3.27% and -6.06 mmol/L (treatment-naive), -2.57% and -4.54 mmol/L (OADs only), -2.96% and 3.51 mmol/L (insulin +/- OADs) all p < 0.05. HbA(1c)< 7% was achieved by 71.4% of patients. Only 0.1% of subjects reported major hypoglycaemia and 73 SADRs were observed without significant difference compared to those at baseline. Body weight did not change significantly. Conclusions: Regardless of previous treatments, insulin initiation or replacement with BIAsp 30 improved glycaemic control without increasing major hypoglycaemia or weight gain in Chinese patients with diabetes.
基金：
Novo NordiskNovo Nordisk
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2009]版：
大类|3 区医学
小类|3 区医学：内科3 区医学：研究与实验
最新[2025]版：
大类|4 区医学
小类|3 区医学：内科4 区医学：研究与实验
JCR分区：
出版当年[2008]版：
Q2MEDICINE, GENERAL & INTERNALQ2MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q1MEDICINE, GENERAL & INTERNALQ3MEDICINE, RESEARCH & EXPERIMENTAL
第一作者单位：[1]China–Japan Friendship Hospital, Beijing, China[*1]China–Japan Friendship Hospital, Department of Endocrinology, Beijing, China
通讯作者：
通讯机构：[1]China–Japan Friendship Hospital, Beijing, China[*1]China–Japan Friendship Hospital, Department of Endocrinology, Beijing, China
推荐引用方式(GB/T 7714)：
Yang Wenying,Gao Yan,Liu Guoliang,et al.Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study[J].CURRENT MEDICAL RESEARCH and OPINION.2010,26(1):101-107.doi:10.1185/03007990903364640.
APA：
Yang, Wenying,Gao, Yan,Liu, Guoliang,Chen, Lulu,Fu, Zuzhi...&Zhao, Zhigang.(2010).Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study.CURRENT MEDICAL RESEARCH and OPINION,26,(1)
MLA：
Yang, Wenying,et al."Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study".CURRENT MEDICAL RESEARCH and OPINION 26..1(2010):101-107
